Navigation Links
Spinal Cord Stimulation Pilot Study for Chronic Angina

St. Jude Medical, Inc. today announced the first patient implant in a pilot study that will preliminarily evaluate if stimulating nerves near the spinal cord will control// chronic chest pain caused by angina.

A 53-year-old Massachusetts woman is the first person to receive this investigational device, called the Genesis? Neurostimulation System. She is one of approximately 1.3 million Americans who suffer from chronic angina, according to the American Heart Association (AHA), with 75,000 new cases of treatment-resistant angina occurring each year.

The Genesis System was developed by St. Jude Medical’s neuromodulation division, Advanced Neuromodulation Systems (ANS).

“There are an increasing number of patients with coronary artery disease who have exhausted available medical and surgical treatment options,” said Roger Laham, M.D., interventional cardiologist with Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, Mass., who is the principal investigator for the trial. “These patients struggle with disabling angina and are commonly referred to as ‘no-option’ patients.”

“The procedure went smoothly,” said Thomas Simopoulos, M.D., interventional pain specialist with the Arnold Pain Management Center at Beth Israel Deaconess Medical Center, who performed the implant. “I am hopeful that spinal cord stimulation will offer a minimally invasive treatment option for patients with chronic, intractable angina.”

Angina is chest pain or discomfort that occurs when the heart muscle does not get as much oxygen as it needs. The pain is often described as a squeezing pain in the chest, shoulders, arms, neck, jaw or back and is sometimes described as feeling like indigestion. Angina is one of the most common symptoms of coronary artery disease which is a leading cause of death in the U.S.

Chronic angina is chest pain that persists. Many with this condition have to live with constant or rec urring pain and loss of function. For a number of these people, medications such as nitroglycerin do not work, and surgical procedures such as angioplasty, stenting or bypass, are considered to be too risky by their doctors.

“The angina clinical trial is an important step forward in our commitment to provide pain solutions for people who don’t have a lot of other options,” said Chris Chavez, president of ANS.

Spinal cord stimulation (SCS) is a therapy that uses mild electrical pulses from an implanted device to stimulate targeted nerves. An SCS device looks and operates much like a cardiac pacemaker, except that instead of sending pulses to the heart, it sends them to leads located near the spinal cord. In this trial, SCS is being tested to see if it interrupts angina pain signals.

To be eligible to participate in the chronic angina pilot study, patients must be 18 years of age or older, have been diagnosed with inoperable coronary artery disease, and be experiencing a minimum of five angina episodes per week. Patients must also be diagnosed with functional class III or class IV angina, categorized according to the Canadian Cardiovascular Society (CCS) scale.


Related medicine news :

1. Spinal Cord Patients Walk Again
2. Hope for Babies Born With Spinal Muscular Atrophy
3. New Findings Could Reduce The Extent Of Spinal Cord Injuries
4. Effective Diagnosis Of Spinal Cord Injuries
5. Treatment May Be Possible For Degenerative Brain And Spinal Cord Disease
6. Titanium Rib Found To Be Effective In Treating Spinal Deformities In Children
7. New Therapy Recommendations For Spinal Complications Of Cancer
8. Nerve regeneration for Spinal cord injuries
9. JRRD Focuses On Issues Such As Spinal Cord Injury and Prosthetics
10. Hope After Spinal Cord Injuries
11. Stem Cell Technology Gives Hope in Spinal Cord Injuries
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology: